Accelerating Access to Critical Therapies for ALS Reauthorization Act of 2026
Bill Summary
Extends funding for the Accelerating Access to Critical Therapies for ALS Act through 2031, continuing support for ALS research and treatment. Reauthorizes existing programs to help people with ALS (Amyotrophic Lateral Sclerosis, a nervous system disease) access new therapies.
Sponsored By
Bill Journey
- Apr 30, 2026
- Jun 17, 2026You Are Here
The committee will review the bill, debate amendments, and vote on whether to advance it to the full chamber.
- TBD
The full chamber debates the bill, may amend it, and votes on whether to pass it.
- TBD
If passed by the first chamber, the other chamber considers, may amend, and votes on the bill.
- TBD
If passed by both chambers, the bill goes to the President to sign into law or veto.
Why It Matters
People with ALS, their families, and researchers studying the disease are affected, as the bill continues funding for research and access to new treatments. ALS patients may have more opportunities to participate in clinical trials and access experimental therapies as a result.
Impact Areas
Support & Opposition
- Democratic1
- Republican1
Documents
1
Full text opens on congress.gov, the official source.
Cosponsors (9)
8 more not shown here — see the full list on congress.gov.
Bill Details
- Health
Summary and impact analysis written by Judy (KnowGov's enrichment AI). Bill metadata, status, sponsor, and any floor votes from Prism. Sections marked “Sample” are placeholders not yet connected to live data.

